17.06.20|Hagar Ravet“To the best of our knowledge, Kamada is the first company globally to complete manufacturing of a plasma-derived IgG product for the treatment of Covid-19,” says CEO of the Nasdaq listed company
22.01.20|Tzally GreenbergIsrael-based private equity fund FIMI became the largest shareholder in Nasdaq and Tel Aviv-listed Kamada in November
24.11.19|Golan Hazani and Tzally GreenbergNasdaq and Tel Aviv-listed Kamada develops protein-based pharmaceuticals for genetic disorders, as well as rabies antibodies and a serum against snake bites
27.08.17|Dror ReichThe plasma-derived drug is used together with the rabies vaccine to treat unvaccinated persons exposed to the virus
More stories in CTech
